Novavax develops vaccines and licenses its Matrix-M adjuvant to drug makers and governments worldwide. It last closed at $7.47 on Nov 20, down 3.24% on the day. The next earnings report for NVAX is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, NVAX reported EPS of -$0.19 on revenue of $68.3M, with revenue down 3.0% from a year ago. Over its last 8 reports the stock moved an average of 9.3% the session after earnings.
AI Auto Pilots
Is NVAX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold NVAX.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on NVAXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
NVAX · as of the Nov 20 close · updated each morning
Turning down, nearing oversold
The stock is 26% below its 20 day and 38% below its 50 day average. It is 25% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 32), near oversold. The nearest support is the Pivot S1 at $7.27, and the nearest resistance the Pivot at $7.63.
Short trendBearish
Long trendNeutral
MomentumWeak
StretchNear oversold
VolatilityHigh, 9.9%/day
Key levels
$13.3852 week high+79.1%
$10.3450 day average+38.4%
$9.48100 day average+26.9%
$9.4120 day average+26.0%
$9.32200 day average+24.8%
$8.09Swing high (Aug 7)+8.3%
$7.82Pivot R1+4.7%
$7.63Pivot+2.1%
$7.47Last close
$7.27Pivot S1−2.7%
$7.15Swing low (Jul 28)−4.3%
$6.2052 week low−17.0%
Indicators
RSI (14)
32.00
Weak, oversold below 30
Neutral
MACD
-0.77
Below its signal line
Bearish
Stochastic
2.5
Near the bottom of its range
Oversold
ADX (14)
28.3
Trending down
Williams %R
-98.9
Oversold below −80, overbought above −20
Oversold
CCI (20)
-137.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−30.7%
Change over 10 sessions
Bearish
ATR (14)
$0.74
Typical daily range, 9.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 20.6%/day
Key levels
$13.3852 week high+79.1%
$10.3450 day average+38.4%
$9.48100 day average+26.9%
$9.4120 day average+26.0%
$9.32200 day average+24.8%
$8.09Swing high (Aug 7)+8.3%
$7.82Pivot R1+4.7%
$7.63Pivot+2.1%
$7.47Last close
$7.27Pivot S1−2.7%
$7.15Swing low (Jul 28)−4.3%
$6.2052 week low−17.0%
Indicators
RSI (14)
41.80
Middle of its range
Neutral
MACD
0.14
Below its signal line
Bearish
Stochastic
24.2
Middle of its range
Neutral
ADX (14)
28.6
Trending down
Williams %R
-99.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-102.1
Oversold below −100, overbought above 100
Oversold
Rate of change
−20.7%
Change over 10 sessions
Bearish
ATR (14)
$1.54
Typical daily range, 20.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NVAX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how NVAX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow NVAX usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for NVAXHow many large options trades hit NVAX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in NVAX in the last 90 days.
From SEC Form 4 filings by NVAX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NVAX is in one of them and how their past NVAX trades turned out.
From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data
About Novavax
Novavax is a vaccine company based in Gaithersburg, Maryland. It develops vaccines using a platform built on protein nanoparticles, and its COVID-19 vaccine, Nuvaxovid, is sold with Sanofi leading commercialization. The company also licenses its Matrix-M adjuvant, which helps vaccines produce a stronger immune response, to partners such as the Serum Institute of India and other drug makers. Its customers include national governments and global pharmaceutical companies.